Research Projects & Grants

  • Individual patient program (IPP) use of Trametinib and Dabrafenib for Multisystem Langerhands Cell Histiocytosis, Role: PI, (11/2019) Status: Completed

Federal

  • COG AAML 1921 / ITCC-054: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, Role: Investigator, Children Oncology Group, (08/2024 - 08/2025) Status: Approved
  • TSLP and pediatric leukemia mechanisms and treatment, Role: Investigator, National Cancer Institute/NIH/DHHS, (06/2024 - 06/2025) Status: Approved
  • COG ARST1431: A randomized phase 3 study of vincristine, dactinomycin, cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS), Role: Investigator, Children Oncology Group, (03/2025 - 03/2026) Status: Approved
  • COG AEWS1221: Randomized phase 3 trial evaluating the addition of the IGF-1R monoclonal antibody ganitumab (AMG 479, NSC# 120449) to multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • Children's Oncology Group (COG) - ACNS0831: Phase III randomized trial of post-radiation chemotherapy in patients with newly diagnosed ependymoma ages 1 to 21 years, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • Children's Oncology Group (COG) AALL1331: Risk-stratified randomized phase III testing of blinatumomab (IND#117467, NSC#765986) in first relapse of childhood B-Lymphoblastic Leukemia (B-ALL), Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG-AREN0534: Treatment for patients with bilateral, multicentric, or bilaterally-predisposed unilateral Wilms tumor, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG - ANBL0032 - Phase III randomized study of Chimeric antibody 14.18 (Ch14.18) in high risk Neuroblastoma following Myeloablative Therapy and autologous stem cell rescue, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • Children's Oncology Group (COG) - ALTE05N1: Umbrella long-term follow-up protocol, Role: Investigator, Children Oncology Group, (11/2024 - 11/2025) Status: Approved
  • Children's oncology group (COG)-AALL08B1: Classification of newly diagnosed acute lymphoblastic leukemia (ALL), Role: Investigator, Children Oncology Group, (10/2023 - 10/2024) Status: Completed
  • Children’s Oncology Group (COG) protocol AOST06B1 – collecting and banking osteosarcoma specimens, Role: Investigator, Children Oncology Group, (05/2023 - 05/2024) Status: Completed
  • COG – ARST0332: Risk-Based Treatment for Non-Rhabdomyosarcoma Sort Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age, Role: Investigator, Children Oncology Group, (03/2023 - 02/2024) Status: Completed
  • COG-ANBLOOP3 - A Phase II/III study of the use of intravenous gammaglobulin therapy for patients with neuroblastoma associated opsoclonus-myoclonus-ataxia syndrome, Role: Investigator, Children Oncology Group, (04/2022 - 04/2023) Status: Completed
  • COG: ARST 0531 - Randomized study of vincristine, dactinomycin and cyclophosphamide (VAC) versus VAC alternating with vincristine and ironotecan (VI) for patients with intermediate-risk rhabdomyosarcoma (RMS), Role: Investigator, Children Oncology Group, (04/2022 - 04/2023) Status: Completed
  • COG ACCL 1333 / BMS CV185-155: a phase III randomized, open label, multi-center study of the safety and efficacy of apixaban for thromboembolism prevention versus no systemic anticoagulant prophylaxis during induction chemotherapy in children with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoma (T or B cell) treated with Pegylated (PEG) L-asparaginase, Role: Investigator, Children Oncology Group, (10/2021 - 10/2022) Status: Completed
  • COG ADVL1722 / Eisai E7389-G000-223:A phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS), Role: Investigator, Children Oncology Group, (01/2021 - 01/2022) Status: Completed
  • COG AAML1321/Novartis CAMN107A2203: A multi-center, open label, non-controlled phase II study to evaluate efficacy and safety of oral nilotinib in pediatric patients with newly diagnosed Ph+ chronic myelogenous leukemia (CML) in chronic phase (CP) or with Ph+ CML in CP or accelerated phase (AP) resistance or intolerant to either imatibib or dasatinib, Role: Investigator, Children Oncology Group, (02/2020 - 02/2021) Status: Completed
  • COG: AALL05B1 - collecting and banking relapsed acute lymphoblastic leukemia research specimens, Role: Investigator, Children Oncology Group, (03/2019 - 03/2020) Status: Completed
  • COG AOST1321: Phase II study of denosumab (IND #127430, NSC #744010), a RANK ligand antibody, for recurrent or refractory osteosarcoma, Role: Investigator, Children Oncology Group, (11/2017 - 11/2018) Status: Completed
  • COG-ACNS02B3- A children's oncology group protocol for collecting and banking pediatric brain tumor research specimens, Role: Investigator, Children Oncology Group, (11/2017 - 11/2018) Status: Completed
  • COG - ABTR01B1 - A Children's Oncology Group protocol for collecting and banking pediatric research specimens including rare pediatric tumors, Role: Investigator, Children Oncology Group, (02/2017 - 02/2018) Status: Completed
  • COG AAML1522 /Celgene CC -5013-AML-002: a phase 2, multicenter, single-arm, open-label study to evaluate the activity, safety and pharmacokinetics of Lenalidomide (Revlimid®) in pediatric subjects from 1 to less than or equal to 18 years of age with relapsed or refractory acute myeloid leukemia, Role: Investigator, Children Oncology Group, (01/2017 - 01/2018) Status: Completed
  • COG-ACCL1131: A phase III open-label trial of caspofungin vs. azole prophylaxis for patients at high-risk for invasive fungal infections (IFI) following allogeneic hematopoietic cell transplantation (HCT), Role: Investigator, Children Oncology Group, (04/2016 - 04/2017) Status: Completed
  • COG AOST1521: A phase 2 study of GPNMB-targeted antibody-drug conjugate, CDX-011 (glembatumumab vedotin, CR011-vcMMAE; IND #128248, NSC #763737), in recurrent or refractory osteosarcoma, Role: Investigator, Children Oncology Group, (04/2016 - 04/2017) Status: Completed
  • Children's Oncology Group (COG) ACNS0821 - Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent/refractory medulloblastoma/CNS PNET of childhood, a COG randomized phase II screening trial, Role: Investigator, Children Oncology Group, (10/2015 - 10/2016) Status: Completed
  • COG-ANHL1131/EICNHL-IGR2009/1593: Intergroup trial for children or adolescents with B-cell non-Hodgkin lymphoma (NHL) or mature B-cell leukemia (B-AL): Evaluation of rituximab efficacy and safety in high risk patients, Role: Investigator, Children Oncology Group, (09/2015 - 09/2016) Status: Completed
  • COG-AAML0631:Risk adapted treatment of newly diagnosed childhood Acute Promyelocytic leukemia (APL) using Arsenic Trioxide (Trisenox, IND#103,331) during consolidation, Role: Investigator, Children Oncology Group, (01/2015 - 01/2016) Status: Completed
  • NCI - Special exception protocol for chimeric MOAB 14:18 (IND #4308, NSC 623408) pediatric patients, Role: Investigator, National Cancer Institute/NIH/DHHS, (09/2014 - 09/2015) Status: Completed
  • Childrens Oncology Group (COG) - ACNS0822: A randomized phase II/III study of vorinostat and local irradiation or temozolomide and local irradiation or bevacizumab and local irradiation followed by maintenance bevacizumab and temozolomide in children with newly diagnosed high-grade gliomas, Role: Investigator, Children Oncology Group, (04/2014 - 04/2015) Status: Completed
  • COG AALL0433 - Intensive treatment for intermediate-risk relapse of childhood b-precursor acute lymphoblastic leukemia (ALL): a randomized trial of vincristine strategies, Role: Investigator, Children Oncology Group, (12/2013 - 12/2014) Status: Completed
  • COG - AALL1122/BMS - CA180-372: A phase 2 multi-center historically-controlled study of dasatinib added to standard chemotherapy in pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL), Role: Investigator, Children Oncology Group, (11/2013 - 11/2014) Status: Completed
  • Children's Oncology Group (COG) - AALL07P1: A phase II pilot trial of bortezomib (PS-341, Velcade®, IND #58,443) in combination with intensive re-induction therapy for children with relapsed acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), Role: Investigator, Children Oncology Group, (11/2013 - 11/2014) Status: Completed
  • COG AREN0321 - Treatment of high risk renal tumors, Role: Investigator, Children Oncology Group, (11/2013 - 11/2014) Status: Completed
  • Children's Oncology Group (COG) - COG - ARST0921: a randomized phase II trial of bevacizumab (avastin) and temsirolimus (torisel) in combination with intravenous vinorelbine and cyclophosphamide in patients with recurrent/refractory rhabdomyosarcoma, Role: Investigator, Children Oncology Group, (09/2013 - 09/2014) Status: Completed
  • COG # AREN0532 - Treatment for very low, low and standard risk favorable histology Wilms tumor, Role: Investigator, Children Oncology Group, (05/2013) Status: Completed
  • COG - ADVL1221: A phase II study of cixutumumab (IMC-A12; IND #100947) in combination with temsirolimus (IND #61010) in pediatric patients with recurrent or refractory solid tumors, Role: Investigator, Children Oncology Group, (07/2012 - 07/2013) Status: Completed

For Profit Organization

  • CCG D9902 A group wide protocol for collecting and banking pediatric cancer research specimens. An intergroup rhabdomyosarcoma study group protocol., Role: Investigator, Children Cancer Group, (05/2023 - 05/2024) Status: Completed
  • EAP-Oncoceutics-ONC018: Expanded access to ONC201 for patients with H3 K27M-mutant and/or midline high grade gliomas, Role: Investigator, Oncoceutics, Inc., (10/2022 - 10/2023) Status: Completed
  • Jazz Pharmaceuticals JZP458-201 (COG AALL1931): An open-label, multicenter study of RC-P in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) following hypersensitivity to E. coli-derived asparaginases, Role: Investigator, Jazz Pharmaceuticals, (01/2022 - 01/2023) Status: Completed
  • Pfizer B0661037: A randomized, open-label, active controlled, safety and descriptive efficacy study in pediatric subjects requiring anti-coagulation for the treatment of a venous thromboembolic event, Role: Investigator, Pfizer Inc., U.S. Pharmaceuticals Group, (11/2021 - 11/2022) Status: Completed
  • Pfizer FRAG-A001-201 (A6301094): A three month prospective open label study of therapy with Fragmin® ( Dalteparin sodium injection) in children with venous thromboembolism with or without malignancies, Role: Investigator, Pfizer Inc., U.S. Pharmaceuticals Group, (05/2017 - 05/2018) Status: Completed

Non-Profit Organization

  • The National Marrow donor Program (NMDP) and Center for International Blood and Marrow Transplant Research (CIBMTR) - Contribution of a Blood Sample to the National Marrow Donor Program's Research Sample Repository, Role: Investigator, National Marrow Donor Program, (09/2024 - 09/2025) Status: Approved
  • PTCTC ONC1701 (End RAD): A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based on conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative, Role: Investigator, Pediatric Blood and Marrow Transplant Consortium, (06/2024 - 06/2025) Status: Approved
  • NMDP and CIBMTR - Protocol for Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries., Role: Investigator, National Marrow Donor Program, (06/2024 - 06/2025) Status: Approved
  • (MAS) Multiple Children's Oncology Group for Non-Industry Funding Sources, Role: Subproject PI, Children's Hospital Philadelphia, (10/2012 - 04/2022) Status: Closed